Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, has chosen 2013 ESMINT at which to announce the European launch of the REVIVE™ SE Thrombectomy Device. It describes REVIVE SE as a next generation clot removal device and claims enhanced navigation through the cerebral vasculature and rapid restoration of blood flow to the brain after an ischemic stroke.
According to the World Health Organization (WHO), 15 million people worldwide have a stroke each year. The European Society of Cardiology says stroke is the second most common cause of death in Europe resulting in almost 1.1 million deaths each year.
Codman Neuro’s REVIVE SE device is a self-expanding basket made out of nitinol that features a closed-ended soft distal tip to capture clots and large fragments with minimal trauma. It is designed with narrower and taller struts than similar devices on the market which the company claims better penetrates and engages more clot and lowers the force required to pass the device through a 0.021 micro-catheter.
The REVIVE SE device may also be used for the non surgical removal of thrombi and emboli with aspiration and injected contrast agents.
REVIVE SE device was CE marked in June 2013 as reported on our pages. following which several institutions in Germany, France, Italy, United Kingdom, Portugal, Spain, Belgium, the Netherlands, Israel, Denmark, Slovakia and Turkey have already begun using the device. The REVIVE SE device is not currently approved for distribution in the United States.
The launch announcement was made at the 5th Congress of European Society of Minimally Invasive Neurological Therapy (ESMINT) in Nice last week, where Codman Neuro is showcasing its range of neurovascular solutions and sponsoring symposia on the interventional treatment of acute stroke and the clinical experience with the enhanced REVIVE SE Thrombectomy Device.
“Our experience with the device has been excellent,” said Professor Stefan Rohde, MD, Head of the Department of Radiology and Neuroradiology at Klinikum Dortmund in Germany and a consultant to Codman Neuro. “We are achieving consistently good recanalization rates and the enhanced navigation eases passage through the cerebral vasculature to the thrombus, which is very important in a time-sensitive operation of this kind.”
“Feedback throughout Europe has been very positive and we are seeing great interest in the REVIVE SE device at ESMINT,” said P. Laxmin Laxminarain, Worldwide President of Codman Neuro. “We believe the device will become an increasingly important treatment option for ischemic stroke patients at institutions throughout Europe.”
Source: Codman Neuro